Detailed Abstract
[Poster Presentation 12 - Biliary & Pancreas (Biliary Disease/Surgery)]
[PP 13-6] ALP TO PLATELET RATIO INDEX (ALPRI) AS A NOVEL PROGNOSTIC MARKER IN INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT (IPNB)
Kantaruthai PIAMPATIPAN 1, VOR LUVIRA 1, KHANISARA KRAPHUNPONGSAKUL 1, ATTAPOL TITAPUN 1, THARATIP SRISUK 1, THEERAWEE TIPWARATORN 1, SUAPA THEERAGUL 1, APIWAT JAREARNRAT 1, VASIN THANASUKARN 1, SUPOT KAMSA-ARD 1, AKE PUGKHEM 1, CHAWALIT PAIROJKUL 1
1 Department of Surgery, Faculty of Medicine, Khon Kaen University, Thailand, 2 Department of Epidemiology And Biostatistics, Faculty of Medicine, Khon Kaen University, Thailand, 3 Department of Pathology, Faculty of Medicine, Khon Kaen University, Thailand
Background : Intraductal papillary neoplasm of the bile duct (IPNB) is recognized as a distinct entity. Numerous studies have reported on prognostic serum markers for IPNB. We introduce the novel marker, ALP-to-Platelet ratio (ALPRI), for its predictive and prognostic utility in IPNB. This research is the inaugural demonstration of the correlation between this marker and the survival of IPNB patients.
Methods : We retrospectively reviewed medical records of 494 patients who were diagnosed with IPNB between January 2007 and December 2022. All clinical parameters were analyzed.
Results : The median of ALPRI was 0.52, and was used as the primary cut point. Patients, therefore, were divided into those with ALPRI < 0.52 (n = 241; 48.8%) and those with ALPRI ≥ 0.52 (n = 253; 51.2%). The demographic and operative variables were comparable between the two groups, with the exception of a higher incidence of abdominal pain in individuals with ALPRI < 0.52, and an increased occurrence of clinical jaundice, fever, INR levels, bilirubin levels, and liver enzyme levels in those with ALPRI ≥ 0.52. The median overall survival time in ALPRI < 0.52 group was significantly greater than ALPRI ≥ 0.52 group (2,672 vs 1,300 days, p < 0.001). The 1-, 3-, and 5-years overall survival rate in ALPRI < 0.52 were 92.3, 72.7, and 62.5% compared to ALPRI ≥ 0.52 that were 85.3, 53.7, and 39.5% respectively.
Conclusions : ALPRI can serve as a novel prognostic marker of IPNB patients. Patients with ALPRI ≥ 0.52 is shown to have lower survival.
Methods : We retrospectively reviewed medical records of 494 patients who were diagnosed with IPNB between January 2007 and December 2022. All clinical parameters were analyzed.
Results : The median of ALPRI was 0.52, and was used as the primary cut point. Patients, therefore, were divided into those with ALPRI < 0.52 (n = 241; 48.8%) and those with ALPRI ≥ 0.52 (n = 253; 51.2%). The demographic and operative variables were comparable between the two groups, with the exception of a higher incidence of abdominal pain in individuals with ALPRI < 0.52, and an increased occurrence of clinical jaundice, fever, INR levels, bilirubin levels, and liver enzyme levels in those with ALPRI ≥ 0.52. The median overall survival time in ALPRI < 0.52 group was significantly greater than ALPRI ≥ 0.52 group (2,672 vs 1,300 days, p < 0.001). The 1-, 3-, and 5-years overall survival rate in ALPRI < 0.52 were 92.3, 72.7, and 62.5% compared to ALPRI ≥ 0.52 that were 85.3, 53.7, and 39.5% respectively.
Conclusions : ALPRI can serve as a novel prognostic marker of IPNB patients. Patients with ALPRI ≥ 0.52 is shown to have lower survival.
SESSION
Poster Presentation 12
Exhibition Hall 3/28/2025 2:20 PM - 3:00 PM